Sun Pharmaceutical Industries Limited (Sun Pharma) and Taro Pharmaceutical Industries Ltd. (Taro) announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash…
Sun Pharmaceutical Industries Limited announced that its Chairman and member of the Board, Israel Makov, will retire from the company upon the completion of his current term post Sun Pharma’s Annual General Meeting on August 29, 2022, after having led the organisation for 10 years. He was appointed a Board member and the Chairman in…
Sun Pharmaceutical Industries Ltd, a Mumbai-based generic pharmaceutical company, announced that it has commenced Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19. The Company received approval from the Drugs Controller General of India (DCGI) for conducting Phase II clinical trials in April this year. The clinical trial will…
Sun Pharmaceutical Industries Ltd, a Mumbai-headquartered pharmaceutical company, announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. The company said that Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation…